CAR-T

As CAR-Ts go from candidates to brands, what's the marketing strategy?

As CAR-Ts go from candidates to brands, what's the marketing strategy?

By

Strategies for differentiating CAR-T therapies emerge in the early days of 2018, while competitors race to catch up with Novartis and Gilead.

Five things for pharma marketers to know: Friday, January 19, 2018

Five things for pharma marketers to know: Friday, January 19, 2018

By

Biogen, UCB reportedly showing interest in Acorda acquisition; Kite Pharma and Pfizer to develop combo lymphoma therapy; hospitals to form generics nonprofit

Five things for pharma marketers to know: Thursday, December 21, 2017

Five things for pharma marketers to know: Thursday, December 21, 2017

By

BI to pay $13.5 million for misleading marketing; ICER: CAR-T therapies more cost-effective than chemotherapy; FDA approves Roche's breast cancer combo therapy

Five things for pharma marketers to know: Tuesday, October 31, 2017

Five things for pharma marketers to know: Tuesday, October 31, 2017

By

Pfizer Q3 revenue driven by Prevnar sales; President Trump's opioid panel presents draft to combat crisis; Novartis seeks FDA approval for CAR-T therapy Kymriah

Five things for pharma marketers to know: Thursday, October 19, 2017

Five things for pharma marketers to know: Thursday, October 19, 2017

By

The FDA approves Kite's CAR-T therapy; Omnicom reports strong Q3 performance for healthcare agencies; Hearst to acquire Rodale, up health presence

Five things for pharma marketers to know: Friday, September 1, 2017

Five things for pharma marketers to know: Friday, September 1, 2017

By

600 patients are eligible for CAR-T therapy; the FDA halts Keytruda combo study for multiple myeloma; the regulator delays decision on Herceptin biosimilar

Novartis' CAR-T therapy, now approved, faces questions about price and side effects

Novartis' CAR-T therapy, now approved, faces questions about price and side effects

By

The Swiss drugmaker is the first to receive FDA approval to market a CAR-T therapy.

Five things for pharma marketers to know: Monday, August 28, 2017

Five things for pharma marketers to know: Monday, August 28, 2017

By

Gilead to acquire Kite; the FDA issues fewest number of warning letters since 2008; the regulator approves BI's Humira biosimilar

Five things for pharma marketers to know: Wednesday, August 23, 2017

Five things for pharma marketers to know: Wednesday, August 23, 2017

By

Doctors fret about price of Novartis' experimental CAR-T therapy; study finds digital pillboxes don't improve adherence; India awards Pfizer vaccine patent

Novartis' CAR-T therapy gets nod from FDA committee

Novartis' CAR-T therapy gets nod from FDA committee

By

The drugmaker is one step closer to a potential approval of its experimental cancer treatment.

Five things for pharma marketers to know: Tuesday, April 18, 2017

Five things for pharma marketers to know: Tuesday, April 18, 2017

By

Novartis gets Breakthrough designation for its CAR-T therapy; Duchesney continues working with Kardashian; new user-fee deal to speed up FDA approvals